IPHYFInnate Pharma

About Innate Pharma (IPHYF)

Innate Pharma (IPHYF) is a Biotechnology company headquartered in Marseille, France whose shares trade over-the-counter on the Pink tier.

Innate Pharma specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by enhancing the capability of the body's own immune cells to recognize and kill cancer cells. The Company has pioneered the development of antibodies that block inhibitory checkpoint receptors on NK cells. Today, Innate Pharma has three first-in-class antibodies in clinical development in immuno-oncology and a pipeline of preclinical candidates to novel targets and mechanisms. Its innovative approach has translated into alliances with leaders in the biopharmaceutical industry such as AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S and Sanofi. Based in Marseille, France, Innate Pharma had 122 employees as at March 31, 2016. The company is listed on Euronext Paris.

IPHYF key facts

Ticker symbol

IPHYF

Market tier

Pink

Sector

Healthcare

Industry

Biotechnology

Headquarters

Marseille, France

Employees

122

Estimated market cap

$55.30M (as of May 12, 2025)

Shares outstanding

38,135,890

Reporting standard

U.S. Reporting: SEC Reporting

Audit status

Audited

Fiscal year end

12/31

Explore more: Biotechnology stocks · Healthcare sector · Pink stocks · OTC stocks starting with I